SaaS Metrics
Academic Publication Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
No description provided.
Semaglutide may lower risk of serious complications in high-risk diabetes
A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and peripheral artery disease (PAD), particularly those at h...
Ozempic Shows Early Anti-Aging Promise, but the Evidence Still Has Major Gaps Researchers Cannot Ignore
UC San Diego RCT found semaglutide slowed biological aging by 9%. But the study had 108 patients, all with HIV. Here is what the evidence shows and what it does not.
Ozempic-like drugs may improve kidney disease outcomes: study
Research shows semaglutide — commonly sold as Ozempic or Wegovy — can improve kidney function and survival rates for people with some chronic diseases, even if they have heart issues.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (M...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials'?
This literature focuses on:
What other academic literature is closely related to 'Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials'?
Yes, highly correlated activity was mapped. An entry titled 'Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials' discusses this: No description provided.
Are there commercial applications of 'Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Semaglutide may lower risk of serious complications in high-risk diabetes' discusses this: A new study suggests GLP-1 medications, such as semaglutide, were associated with better overall outcomes in people with type 2 diabetes and periph...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.